Vaccinex, INC

Bala S. Manian resigned from the Vaccinex, Inc. Board of Directors on March 18, 2025, with his departure not stemming from any disagreements with the company.

Vaccinex, Inc. has announced its intention to delist its common stock from the Nasdaq Stock Market following a suspension of trading and a determination by the Nasdaq Hearings Panel.

Vaccinex, Inc. will be delisted from the Nasdaq Stock Market due to not meeting the minimum stockholders' equity requirement and will transition to the OTC Markets Group.

Vaccinex, Inc. has successfully completed a private placement, raising approximately $2.15 million through the issuance of common stock and pre-funded warrants.

Vaccinex, Inc. has received a delisting notice from Nasdaq after failing to meet minimum equity requirements, and intends to appeal the decision.

Vaccinex, Inc. has raised approximately $6.2 million through the exercise of existing warrants and the issuance of new warrants in a private placement.

Vaccinex reported its Q3 2024 financial results, highlighting a net loss and ongoing concerns about its ability to continue as a going concern, while also announcing positive clinical trial data for its Alzheimer's drug candidate.

Vaccinex, Inc. released its second quarter 2024 financial results, detailing ongoing clinical trial progress and financial updates, while also noting concerns about its ability to continue as a going concern.

Vaccinex, a clinical-stage biotech company, reported a net loss of $3.9 million for the first quarter of 2024, while also addressing Nasdaq compliance issues and securing new funding.

Vaccinex's 10-K filing reveals a clinical-stage biotech company prioritizing Alzheimer's disease treatment while navigating financial challenges and strategic partnerships.

Vaccinex, Inc. files an amendment to its 2023 annual report to include the conformed signature of its independent auditor, Deloitte & Touche LLP, which was inadvertently omitted from the original filing.

Vaccinex Inc.'s 10-K filing outlines its clinical-stage biopharmaceutical activities, focusing on pepinemab development for neurodegenerative diseases and cancer, alongside financial results and future strategies.

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., has increased his holdings through the acquisition of common stock and the exercise of pre-funded warrants.

Vaccinex CEO Maurice Zauderer and Vaccinex (Rochester), L.L.C. reported transactions involving the acquisition of common stock and holdings of derivative securities.

CEO Maurice Zauderer and Vaccinex (Rochester), L.L.C. report changes in beneficial ownership of Vaccinex, Inc. stock and warrants following warrant exercise price adjustments.

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., reports adjustments to warrant exercise prices and acquisition of shares through warrant exercises and inducement agreements.

Albert Friedberg, a director and 10% owner of VaccinEx, Inc., reports acquiring 100 shares of common stock at $4.51 per share on August 9, 2024, and discloses beneficial ownership through related entities.

Albert Friedberg, a director and 10% owner of VaccinEx, Inc., along with FCMI Parent Co., reported changes in beneficial ownership of the company's common stock and warrants.

Vaccinex, Inc. is holding its annual stockholder meeting on May 9, 2024, to vote on director elections, executive compensation, and an amendment to its 2018 Omnibus Incentive Plan.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in Vaccinex, Inc.'s common stock as of December 31, 2024.